Novocure Ltd. logo

Novocure Ltd. (038)

Market Closed
24 Jun, 14:31
14. 30
+0.14
+0.95%
- Market Cap
- P/E Ratio
0% Div Yield
0 Volume
-2.03 Eps
14.16
Previous Close
Day Range
14.16 14.3
Year Range
12.96 32.29
Want to track 038 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 7 days

Summary

038 closed Tuesday higher at €14.3, an increase of 0.95% from Monday's close, completing a monthly decrease of -15.63% or €2.65. Over the past 12 months, 038 stock lost -47.25%.
038 is not paying dividends to its shareholders.
The last earnings report, released on Jun 05, 2025, exceeded the consensus estimates by 0.15%. On average, the company has fell short of earnings expectations by -0.02%, based on the last three reports. The next scheduled earnings report is due on Jul 24, 2025.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

038 Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.
NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?

NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?

NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks | 2 weeks ago
What Makes NovoCure (NVCR) a New Buy Stock

What Makes NovoCure (NVCR) a New Buy Stock

NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 4 weeks ago
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial

NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial

Novocure's PANOVA-3 trial shows that the TTFields combo boosts survival in pancreatic cancer, hitting the primary endpoint.

Zacks | 1 month ago

Novocure Ltd. Dividends

038 is not paying dividends to its shareholders.

Novocure Ltd. Earnings

24 Jul 2025 (In 1 week) Date
-
Cons. EPS
-
EPS
24 Jul 2025 (In 1 week) Date
-
Cons. EPS
-
EPS
5 Jun 2025 Date
-
Cons. EPS
-
EPS
27 Feb 2025 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
-
Cons. EPS
-
EPS
038 is not paying dividends to its shareholders.
24 Jul 2025 (In 1 week) Date
-
Cons. EPS
-
EPS
24 Jul 2025 (In 1 week) Date
-
Cons. EPS
-
EPS
5 Jun 2025 Date
-
Cons. EPS
-
EPS
27 Feb 2025 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
-
Cons. EPS
-
EPS

Novocure Ltd. (038) FAQ

What is the stock price today?

The current price is €14.30.

On which exchange is it traded?

Novocure Ltd. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is 038.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Jul 24, 2025.

Has Novocure Ltd. ever had a stock split?

No, there has never been a stock split.

Novocure Ltd. Profile

Medical - Instruments & Supplies Industry
Healthcare Sector
Ashley Cordova CEO
XDUS Exchange
JE00BYSS4X48 ISIN
JE Country
1,488 Employees
- Last Dividend
- Last Split
2 Oct 2015 IPO Date

Overview

NovoCure Limited is a pioneering oncology company that specializes in the development, manufacture, and commercialization of its innovative tumor treating fields (TTFields) devices for the treatment of various solid tumor cancers. Founded in 2000, NovoCure maintains a strong international presence with operations in the United States, Germany, Japan, Greater China, and other global markets. The company is headquartered in Saint Helier, Jersey, highlighting its global reach and commitment to advancing cancer treatment worldwide. NovoCure's groundbreaking approach focuses on utilizing TTFields technology to target cancer cells, offering a novel treatment option beyond traditional methods. With ongoing clinical trials aimed at expanding the applications of TTFields, NovoCure continues to explore the potential of its technology in treating a wide range of cancers, including brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.

Products and Services

  • Optune Gio:
  • Optune Gio is one of NovoCure's flagship TTFields devices, designed specifically for the treatment of glioblastoma, a highly aggressive form of brain cancer. This device represents a significant advancement in the field of oncology, offering a non-invasive treatment option that utilizes low-intensity electric fields to disrupt cancer cell division and growth. By targeting glioblastoma cells while sparing healthy tissue, Optune Gio offers a promising treatment alternative for patients with this challenging condition.

  • Optune Lua:
  • Optune Lua is another innovative TTFields device offered by NovoCure, tailored for the treatment of malignant pleural mesothelioma, a rare cancer linked to asbestos exposure that affects the lining of the lungs. Like Optune Gio, Optune Lua employs TTFields technology to selectively target cancer cells, aiming to inhibit their proliferation and induce cell death. This device provides a critical option for mesothelioma patients, for whom treatment options are often limited and prognosis is typically poor.

Contact Information

Address: No. 4 The Forum
Phone: 44 15 3475 6700